Physician profile
John E Staniland
NPI 1447264908
$4,275.75
in general payments reported to CMS, 2019-2025
46 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $644 · 2021: $1,158 · 2022: $768 · 2023: $760 · 2024: $384 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,267.50 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $677.49 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $366.40 | 2019-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $317.05 | 2019-2020 | |
| Amarin Pharma, INC. | $306.86 | 2019-2022 | |
| Antares Pharma, INC. | $230.68 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Glaxosmithkline, LLC. | $198.27 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $171.20 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $146.78 | 2019-2024 | Airsupra, Breztri |
| Abbvie INC. | $140.94 | 2021-2024 | |
| Arbor Pharmaceuticals, INC. | $125.04 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $105.17 | 2023 | Quviviq |
| Halozyme INC | $96.40 | 2023 | |
| Ibsa Pharma INC. | $93.76 | 2020-2024 | Tirosint, Tirosint, Licart |
| Lundbeck LLC | $86.19 | 2021-2024 | Vyepti |
| Astellas Pharma US INC | $76.67 | 2019-2025 | Veozah |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Staniland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.